Navigation Links
AMDL Reports Going Concern Qualification
Date:5/9/2008

TUSTIN, Calif., May 9 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), an international vertically integrated specialty pharmaceutical company with operations in China through its wholly owned subsidiary, Jade Pharmaceutical Inc., today announced that its consolidated financial statements for the year ended December 31, 2007, which were included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 14, 2008, contained a 'going concern' qualification from its independent registered public accounting firm KMJ Corbin & Company LLP. This announcement is in compliance with the AMEX Company Guide Rule 610(b) requiring a public announcement of the receipt of an audit opinion that contains a going concern qualification. This announcement does not reflect any change or amendment to the consolidated financial statements as filed. Further information regarding the going concern qualification is contained in AMDL's Annual Report on Form 10-K for the year ended December 31, 2007.

Mr. Gary Dreher, CEO, stated, "Significant improvements in AMDL's China operations combined with other recently announced events provide a financial platform for the Company to improve its sales and earning profile during the second half of FY2008 and beyond, giving us greater confidence in AMDL's financial performance in 2008. Accordingly, we anticipate AMDL will be to in a position to have our auditors remove the 'going concern' qualification after the end of the current fiscal year." The business improvement and opportunities referenced above include:

* FY2007 Sales of $15 million and, Gross Profits of $8.1 million;

* In-licensed Human Papilloma Virus ("HPV") Diagnostic Test;

* Signed LOI for the Purchase a China Based Pharmaceutical Distribution

Company;

* Signed an MOU for 200 Store Distribution Arrangements for theGoodnak

Product Line;

About Jade Pharmaceutical: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

VoiceMail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AutoImmune Inc. Reports 2008 First Quarter Financial Results
2. Bioniche Reports Fiscal 2008 Third Quarter
3. DRAXIS Health Reports Results for the First Quarter of 2008
4. Par Pharmaceutical Reports First Quarter 2008 Results
5. Air Methods Reports 1Q2008 Results and 2Q2008 Update
6. Genoptix Reports Strong Financial Results for First Quarter 2008
7. IDM Pharma Reports First Quarter Financial Results
8. General Nutrition Centers, Inc. Reports First Quarter 2008 Financial Results
9. Orchid Cellmark Reports First Quarter 2008 Financial Results
10. Neurotechnology Industry Reports Record Global Growth of $130.5 Billion in 2007
11. Micromet, Inc. Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when ... president of the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and ... goals are cast aside. , That’s why one of her first decisions when her ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... businesses recover after a disaster, announced today the acquisition of Hawaii DKI. Hawaii ... , “Investing in like-minded companies who excel at service and response ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), ... the ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient ... , “Since our Pay It Forward program began, we are proud to ...
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... BioSciences, Inc. (NASDAQ: SGMO ), the leader ... quarter and full year 2015 financial results and ... editing," said Edward Lanphier, Sangamo,s president and chief ... leads the therapeutic genome editing field and we ... our ground-breaking genome editing programs through IND enabling ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
(Date:2/9/2016)... --  AllCare Plus Pharmacy announced today that it ... ® for Home Care Accreditation by ... Seal of Approval ® is a symbol of ... and effective care.  --> ... on-site survey in January 2016. The survey reflected compliance ...
Breaking Medicine Technology: